UPB
3:30 AM
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1) and exhaled nitric oxide (FeNO) with every 12-week dosing – – The Company remains on track to
Presentation / Abstract • Phase 2ERS oral presentation Tue, Sep 8, 2026upstreambio.com